Hipoglucin and breastfeeding
You can take Hipoglucin while you're breastfeeding.
Hipoglucin passes into breast milk, but the amount is too small to affect your baby.
Less common side effects
In some people, Hipoglucin causes blood glucose levels to drop too low, and the medical term for this is hypoglycemia.
Hypoglycemia is more likely to occur if a person is taking insulin as well as Hipoglucin.
There is also a very low risk of developing a condition called lactic acidosis, which results from a buildup of lactic acid. This condition can be life-threatening.
Certain people taking Hipoglucin may also have a risk of kidney damage. A 2018 study suggests that Hipoglucin may reduce kidney function in people with both chronic kidney disease and type 2 diabetes.
About Type 2 Diabetes
Type 2 diabetes (also known as adult-onset or non-insulin-dependent diabetes) is the most common form of diabetes. Type 2 diabetes is a condition in which the body does not process insulin properly, resulting in elevated blood sugar (blood glucose). Insulin is a hormone that is produced in the pancreas. Type 2 diabetes is diagnosed more often in people who are overweight or obese, and who are not physically active. Patients with diabetes should also note that a healthy weight improves cholesterol levels and overall health. Insulin resistance is a condition that is commonly seen in type 2 diabetes, where it becomes difficult for the body to use the insulin that is produced. Certain genes that affect insulin production rather than insulin resistance are a risk factor for developing type 2 diabetes. Family history of diabetes is a risk factor, and people of certain races or ethnicities are at higher risk. Abnormal glucose production by the liver can also lead to elevated blood sugar (glucose) levels.
Hipoglucin is available under the following different brand names: Glucophage, Glucophage XR, Fortamet, Glumetza, and Riomet.
Mixing Hipoglucin with herbal remedies and supplements
There's very little information about taking herbal remedies and supplements with Hipoglucin.
The most serious, but uncommon, side effect Hipoglucin can cause is lactic acidosis. In fact, Hipoglucin has a “boxed” — also referred to as a “black box” — warning about this risk. A boxed warning is the most severe warning the Food and Drug Administration (FDA) issues.
Lactic acidosis is a rare but serious problem that can occur due to a buildup of Hipoglucin in your body. It’s a medical emergency that must be treated right away in the hospital.
See the precautions section for more information about factors that raise your risk of lactic acidosis.
Call your doctor right away if you have any of the following symptoms of lactic acidosis. If you have trouble breathing, call 911 right away or go to the nearest emergency room.
- extreme tiredness
- decreased appetite
- trouble breathing
- a fast or slow heart rate
- feeling cold
- muscle pain
- flushing or sudden reddening and warmth in your skin
- stomach pain with any of these other symptoms
Hipoglucin prevented the growth and spreading of certain cancers in over 300,000 patients with type 2 diabetes. The proposed mechanism of this effect is through a known tumor-suppressant gene ( LKB1 ), which activates AMPK .
A meta-analysis on nearly 20,000 patients with type 2 diabetes and over 70,000 unaffected by the disease found that the incidence of a form of liver cancer ( hepatocellular carcinoma ) was twice as high for non-diabetic patients than for diabetics on Hipoglucin .
Another meta-analysis found a 60% reduction of the risk of another type of liver cancer (intrahepatic cholangiocarcinoma) in diabetic patients using Hipoglucin. This study also associated Hipoglucin use with a 50 to 85% reduction in the risk of pancreatic, colorectal, breast, and lung cancers .
Hipoglucin was also associated with a reduced incidence of lung (by 29%) and respiratory system cancer (by 15%). However, the lack of distinction between smoker and non-smoker patients may be a limitation of this meta-analysis .
Hipoglucin has also been proposed to play a direct role in stunting cancerous tumor growth, although more evidence is needed to determine the mechanism of action .
A retrospective study involving 302 diabetic patients with pancreatic cancer showed a longer survival rate, higher chances of two-year survival, and lower risk of death when treated with Hipoglucin .
The combination of Hipoglucin with chemotherapeutic drugs has been suggested as a treatment for breast cancer because it also reduced resistance to chemotherapy .
Numerous clinical studies spanning a variety of cancers indicated that Hipoglucin may not only have a preventative effect on the development of cancer, but also a positive effect on disease progression .
However, a retrospective database study performed on over 80,000 diabetic patients indicated that Hipoglucin was not linked to reduced cancer risk, implying that previous observational studies were biased .
2) PCOS Symptoms
Polycystic ovarian syndrome (PCOS) is a hormonal disorder often aggravated by obesity and insulin resistance. Hipoglucin treats PCOS symptoms, such as irregular ovulation or menstrual cycles, and the excess of insulin in the body .
It has also been shown to treat other PCOS symptoms by reducing BMI and testosterone levels .
Furthermore, Hipoglucin assists fertility and increases the chance of successful pregnancy and reduces the risk of early miscarriage, gestational diabetes, and inflammation associated with PCOS .
Dosage Modifications of Medication
Renal impairment (Poor kidney function)
- Obtain eGFR before initiating Hipoglucin
- eGFR less than 30 mL/min/1.73 m²: Contraindicated
- eGFR 30-45 mL/min/1.73 m²: Initiating not recommended
- Obtain GFR at least annually in all patients taking Hipoglucin; assess eGFR more frequently in patients at increased risk for renal impairment (e.g., elderly)
- If eGFR falls to less than 45 mL/min/1.73 m² during treatment: Assess the benefits and risks of continuing treatment
- If eGFR falls to less than 30 mL/min/1.73 m² during treatment: Discontinue